CompletedNCT00195767
Long-term safety of divalproex extended release for mania in children and teens
About this title
Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents
Read the official source — NCT00195767Medication studyAges 10–17United StatesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
- Listed locations
- North ChicagoSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 150
- Sponsor
- Abbott
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00195767
- Official title
Show the full official title
An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
North Chicago
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Abbott.
Did this study involve medication?
Yes. The study involved medication, including divalproex sodium.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
